According to MarketsandMarkets™, the latest research report, “Cancer Vaccines Market by Type (Preventive, Therapeutic [Neoantigen]), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Specialty Clinics) – Global Forecast to 2032,” the market is projected to grow from USD 9.84 billion in 2024 to USD 15.00 billion by 2032, registering a CAGR of 5.4%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30645011
What is driving this growth, and why does it matter now?
The expansion of the cancer vaccines market is primarily fueled by increasing global awareness of preventive healthcare, coupled with significant technological advancements in immunotherapy. As cancer incidence continues to rise worldwide, governments and healthcare organizations are intensifying efforts to implement large-scale vaccination programs and early prevention strategies.
How are innovations shaping the future of this market?
Substantial investments in research and development—particularly in neoantigen-based therapeutic vaccines—are unlocking new opportunities. Promising clinical outcomes from pipeline candidates such as Tedopi, mRNA-4157, and GLSI-100 are reinforcing confidence among stakeholders and accelerating commercialization timelines. These advancements signal a shift toward personalized cancer treatment approaches, aligning with broader precision medicine trends.
From a segmentation standpoint, preventive cancer vaccines accounted for the largest market share in 2023. This dominance is attributed to rising public health awareness, increased government-led immunization initiatives, and the proven efficacy of vaccines in reducing cancer risk. Meanwhile, therapeutic vaccines are expected to witness robust growth, driven by expanding oncology R&D, strategic collaborations, and growing funding for next-generation vaccine platforms.
Which indications are leading adoption?
Cervical and related cancers emerged as the dominant segment in 2023, largely due to the widespread success of HPV-targeted vaccines such as Gardasil and Cervarix. High vaccination coverage in developed regions, particularly North America and Europe, combined with mandatory school-based immunization programs, continues to strengthen this segment. Additionally, ongoing clinical research targeting melanoma, non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC) is expected to further diversify and expand the application landscape.
Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=30645011
Where is the market growing most rapidly?
While Asia Pacific held the largest market share in 2023, North America is anticipated to register the highest CAGR through 2032. Favorable regulatory frameworks, strong clinical infrastructure, and a growing focus on personalized medicine are key growth enablers in the region. The United States leads with initiatives such as the Vaccines for Children (VFC) program, ensuring widespread vaccine accessibility, while Canada’s universal HPV vaccination programs continue to drive adoption.
Who are the key players shaping this competitive landscape?
Leading companies operating in the global cancer vaccines market include Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US), and Shanghai Zerun Biotechnology Co., Ltd. (China). These organizations are actively investing in innovation, strategic partnerships, and global expansion to strengthen their market positions.
Related Reports:
Vaccines Market - Global Forecast to 2030
Veterinary Vaccines Market - Global Forecast to 2030
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com
